Brokerages Set iRhythm Technologies (NASDAQ:IRTC) PT at $219.23

Shares of iRhythm Technologies (NASDAQ:IRTC) have received a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $211.6154.

Several brokerages have weighed in on IRTC. Freedom Capital upgraded iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. Citigroup lifted their price objective on iRhythm Technologies from $205.00 to $242.00 and gave the company a “buy” rating in a report on Friday, October 31st. Truist Financial set a $200.00 target price on shares of iRhythm Technologies in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $244.00 target price on shares of iRhythm Technologies in a research report on Monday, January 12th. Finally, Canaccord Genuity Group lowered their price target on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a research report on Friday.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Price Performance

Shares of IRTC stock opened at $150.96 on Wednesday. The company has a market capitalization of $4.88 billion, a P/E ratio of -107.83 and a beta of 1.06. The company’s 50-day simple moving average is $164.65 and its two-hundred day simple moving average is $171.48. iRhythm Technologies has a one year low of $92.52 and a one year high of $212.00. The company has a debt-to-equity ratio of 4.25, a current ratio of 4.63 and a quick ratio of 4.48.

iRhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.27. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The firm had revenue of $208.89 million during the quarter, compared to analyst estimates of $202.61 million. During the same quarter in the previous year, the business earned ($0.04) earnings per share. iRhythm Technologies’s quarterly revenue was up 27.1% on a year-over-year basis. As a group, equities analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

Insider Buying and Selling

In other news, insider Chad Patterson sold 280 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $51,752.40. Following the completion of the transaction, the insider directly owned 43,387 shares of the company’s stock, valued at approximately $8,019,219.21. The trade was a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patrick Michael Murphy sold 2,478 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $458,008.74. Following the sale, the insider owned 53,281 shares of the company’s stock, valued at $9,847,927.23. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.68% of the company’s stock.

Hedge Funds Weigh In On iRhythm Technologies

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of iRhythm Technologies by 48.4% in the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock valued at $33,000 after buying an additional 60 shares in the last quarter. Ascent Group LLC lifted its position in iRhythm Technologies by 0.7% during the fourth quarter. Ascent Group LLC now owns 9,587 shares of the company’s stock valued at $1,701,000 after acquiring an additional 70 shares during the last quarter. WoodTrust Financial Corp lifted its position in iRhythm Technologies by 0.7% during the fourth quarter. WoodTrust Financial Corp now owns 10,070 shares of the company’s stock valued at $1,787,000 after acquiring an additional 70 shares during the last quarter. US Bancorp DE boosted its stake in iRhythm Technologies by 7.8% in the third quarter. US Bancorp DE now owns 1,042 shares of the company’s stock valued at $179,000 after acquiring an additional 75 shares in the last quarter. Finally, State of Wyoming grew its holdings in iRhythm Technologies by 16.0% in the fourth quarter. State of Wyoming now owns 616 shares of the company’s stock worth $109,000 after purchasing an additional 85 shares during the last quarter.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.